Literature DB >> 31352608

Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims.

Afsaneh Barzi1, Dawn L Hershman2, Cathee Till3, William E Barlow3, Scott Ramsey4, Heinz-Josef Lenz5, Howard S Hochster6, Joseph M Unger3.   

Abstract

To explore the rates of osteoporosis (diagnosis and screening) and fractures in colorectal cancer survivors (CRCS), records of clinical trial enrollees was linked to Medicare. Female/male risk of fracture in CRCS is 74% higher than general population. Less than 30% of male and female CRCS receive osteoporosis screening. Osteoporosis is a significant morbidity in CRCS.
INTRODUCTION: In the USA, the population of colorectal cancer survivors (CRCS) is on the rise. Calcium and vitamin D are the common thread between colorectal cancer and osteoporosis. We set to explore the patterns and prevalence of osteoporosis (OP) and osteoporotic fractures (OF) in CRCS who received fluorouracil-based therapy on SWOG trials.
METHODS: Data for CRCS from three SWOG phase III treatment trials between 1994 and 2000 (N = 3775) were linked to Medicare claims (N = 1233). OP was identified using ICD9 and HCPCS codes; OF was defined using a more restricted set of codes. We compared patterns of OP, OF, and screening for OP by gender in CRCS. Given the gender disparities in the rates of OP and OF, we used data from the National Health Interview Survey (NHIS) and the National Hospital Discharge Survey (NHDS) to assess the ratio of OF in females and males in general population.
RESULTS: Forty-seven percent of females and 15% of men CRCS had OP claims. Female CRCS were more likely than males to have OP (HR = 4.76 [3.77-6.01], p < 0.0001) and OF (HR = 2.64 [2.04-3.42], p < 0.0001). In the general population, the female to male ratio of OF was 1.67 as opposed to 2.90 in CRCS, indicating a significantly larger gender disparity of OF in CRCS (p < 0.001). Only 7% of men and 27% of women CRCS had OP screening.
CONCLUSION: Despite a low rate of OP screening, the gender disparity of OF in CRCS is more pronounced than the general population. These findings provide an impetus for studying OP and OF in CRCS.

Entities:  

Keywords:  Colorectal cancer; Gender disparity; Medicare claims; Osteoporosis; Survivorship

Year:  2019        PMID: 31352608      PMCID: PMC6852789          DOI: 10.1007/s11657-019-0629-7

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  38 in total

1.  Low bone mineral density linked to colorectal adenomas: a cross-sectional study of a racially diverse population.

Authors:  Shilpa Gowda; Seth Lipka; Ashley H Davis-Yadley; Huafeng Shen; Jeffrey Silpe; Andy White; Sam Satler; Dustin Luebbers; James Statler; Anna Zheng; Joshua Elder; Albin Abraham; Prakash Viswanathan; Paul Mustacchia
Journal:  J Gastrointest Oncol       Date:  2015-04

2.  The association of radiographically detected vertebral fractures with back pain and function: a prospective study.

Authors:  M C Nevitt; B Ettinger; D M Black; K Stone; S A Jamal; K Ensrud; M Segal; H K Genant; S R Cummings
Journal:  Ann Intern Med       Date:  1998-05-15       Impact factor: 25.391

3.  Vitamin D signaling regulates proliferation, differentiation, and myotube size in C2C12 skeletal muscle cells.

Authors:  Christian M Girgis; Roderick J Clifton-Bligh; Nancy Mokbel; Kim Cheng; Jenny E Gunton
Journal:  Endocrinology       Date:  2013-11-26       Impact factor: 4.736

4.  Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study.

Authors:  Christy G Woolcott; Lynne R Wilkens; Abraham M Y Nomura; Ronald L Horst; Marc T Goodman; Suzanne P Murphy; Brian E Henderson; Laurence N Kolonel; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

5.  "Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures?

Authors:  J R Curtis; A J Taylor; R S Matthews; M N Ray; D J Becker; L C Gary; M L Kilgore; M A Morrisey; K G Saag; A Warriner; E Delzell
Journal:  Osteoporos Int       Date:  2009-01-29       Impact factor: 4.507

6.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

7.  Bone density and fracture risk in men.

Authors:  L J Melton; E J Atkinson; M K O'Connor; W M O'Fallon; B L Riggs
Journal:  J Bone Miner Res       Date:  1998-12       Impact factor: 6.741

Review 8.  Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Stefanos Bonovas; Gionata Fiorino; Theodore Lytras; Alberto Malesci; Silvio Danese
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

9.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

Review 10.  Management of cancer treatment-induced bone loss.

Authors:  Robert E Coleman; Emma Rathbone; Janet E Brown
Journal:  Nat Rev Rheumatol       Date:  2013-03-19       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.